Patent · US Active

Stable amyloid beta monomers and oligomers

US9688734B2 · kind B2 · utility

2Cited by

1References

25Claims

0Family size

Assignee

ALZINOVA AB · SE

Inventors

Torleif Härd · Uppsala, SE
Anders Sandberg · Blombacka, SE

Key dates

Filing date	Apr 14, 2009
Grant date	Jun 27, 2017
Priority date	—
Expiry date	Jan 2, 2030

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.